Direct oral anticoagulants against activated factor X and thrombin were the last milestone in
thrombosis treatment. Step by step, they replaced antivitamin K and heparins in most of their …

Background Despite the progress in comprehending molecular design principles and
biochemical processes associated with thrombin inhibition, there is a crucial need to …

Direct oral anticoagulant drugs (DOACs) interfere with the coagulation process, thus
improving patient care for those who require anticoagulant treatment. This study presents a …

Background Publication of the BRIGHT-4 trial results has restimulated discussion about the
optimal periprocedural antithrombotic strategy for patients undergoing percutaneous …

Background: Advanced liver diseases are characterized by a number of changes in the
hemostatic system. Due to the occurrence of bleeding events in patients with liver cirrhosis …

Thromboembolic disorders, arising from abnormal coagulation, pose a significant risk to
human life in the modern world. The FDA has recently approved several anticoagulant drugs …

Anticoagulation options have expanded over the last few decades, providing a greater
variety of medications for thromboembolic disease prevention and management. Direct oral …

The heparin anti-Xa assay is affected by the use of direct oral anticoagulants (DOACs) and
is utilized in the management of intravenous unfractionated heparin. Patients with non-ST …

Background Since the late 2000s, Europe has granted approval for various thrombotic risk‐
related uses of direct oral anticoagulants (DOACs). Unlike traditional anticoagulants, DOACs …

Background: Diagnosis of cerebrovascular disease is based on both clinical and
radiological findings, however, they do not always correlate. Aims: To investigate ischemic …